A 24-week, open-label extension study to investigate the long-term safety, tolerability, and efficacy of 13.3 mg/24 h rivastigmine patch in patients with severe Alzheimer disease

Martin R. Farlow, George T. Grossberg, Carl H. Sadowsky, Xiangyi Meng, Drew M. Velting

Research output: Contribution to journalArticle

5 Scopus citations

Fingerprint Dive into the research topics of 'A 24-week, open-label extension study to investigate the long-term safety, tolerability, and efficacy of 13.3 mg/24 h rivastigmine patch in patients with severe Alzheimer disease'. Together they form a unique fingerprint.

Medicine & Life Sciences